Talaris Therapeutics, Inc. is under the spotlight for raising funds. It isn’t the first time a company has received so much attention on news like so. Funds are filed for and received for numerous reasons, especially by biotechnological companies.
If you’re curious to find out more about the cause behind the funding, it’s worth reading till the end.
The $115 million funding is a Series B financing. While this was closed, Phase 3 registration trials were going on. Talaris is conducting these trials for its main product. It’s for supporting living donor kidney transplants. Besides, the company has scheduled the Phase 2 trial for next year.
Interestingly, numerous companies such as Tend are securing Series B financing. This act is also proving to be a useful ste…